FOR INVASIVE INFECTIONS
How HelixBind is Changing Care
Redefining the standard of CARE
HelixBind is developing an innovative diagnostic platform to revolutionize care for bloodstream infections.
Its proprietary platform provides faster, more accurate, and more informative microbiology results, assisting clinicians in precisely identifying invasive infections and developing personalized antimicrobial interventions for infected patients.
Better and faster diagnostics can reduce the spread of antimicrobial resistance, improve outcomes, and save lives.
HelixBind in the News
RAPID & ACCURATE IDENTIFICATION
HelixBind is growing and actively looking for talented individuals.
CAREERS at helixbind
Explore HelixBind Technology
SUPPORTING BETTER OUTCOMES
The Challenge of Sepsis
Sepsis, caused by a severe immune response to a bloodstream infection, is a major global health crisis.
Every year in the US, there are 1.7M cases, and more than 270,000 of those patients will not survive. Globally the situation is more dire, with 30M annual cases leading to well over 6M deaths.
Prognosis for septic patients deteriorates hourly. Fast and accurate identification and characterization of the infection is crucial so that physicians can initiate the appropriate antimicrobial treatment as soon as possible.
identify the infection faster
HELIXBIND
RESULTS IN 4 HOURS
Traditional blood culture test
RESULTS IN 2-3 DAYS
HelixBind results can help guide appropriate clinical decisions enabling selection of the best treatment options long before culture results become available.
CONTACT HELIXBIND
HelixBind, Inc.
1300 Massachusetts Avenue, Unit 103
Boxborough, MA 01719
For general inquiries, contact us at:
info@helixbind.com
774-300-8557
For partnerships and business development:
bd@helixbind.com
For press: